Logo image of PHIL.MI

PHILOGEN SPA (PHIL.MI) Stock Fundamental Analysis

Europe - BIT:PHIL - IT0005373789 - Common Stock

23.9 EUR
+0.4 (+1.7%)
Last: 10/20/2025, 7:00:00 PM
Fundamental Rating

7

PHIL gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 76 industry peers in the Biotechnology industry. PHIL has an excellent financial health rating, but there are some minor concerns on its profitability. PHIL is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes PHIL very considerable for growth investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year PHIL was profitable.
PHIL had a positive operating cash flow in the past year.
In the past 5 years PHIL reported 4 times negative net income.
PHIL had negative operating cash flow in 4 of the past 5 years.
PHIL.MI Yearly Net Income VS EBIT VS OCF VS FCFPHIL.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

1.2 Ratios

The Return On Assets of PHIL (28.81%) is better than 93.42% of its industry peers.
With an excellent Return On Equity value of 36.49%, PHIL belongs to the best of the industry, outperforming 96.05% of the companies in the same industry.
The Return On Invested Capital of PHIL (21.08%) is better than 94.74% of its industry peers.
Industry RankSector Rank
ROA 28.81%
ROE 36.49%
ROIC 21.08%
ROA(3y)5.82%
ROA(5y)-1.99%
ROE(3y)6.79%
ROE(5y)-3.69%
ROIC(3y)N/A
ROIC(5y)N/A
PHIL.MI Yearly ROA, ROE, ROICPHIL.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20 30

1.3 Margins

PHIL has a Profit Margin of 58.33%. This is amongst the best in the industry. PHIL outperforms 97.37% of its industry peers.
PHIL's Profit Margin has improved in the last couple of years.
PHIL's Operating Margin of 49.47% is amongst the best of the industry. PHIL outperforms 96.05% of its industry peers.
With a decent Gross Margin value of 74.04%, PHIL is doing good in the industry, outperforming 67.11% of the companies in the same industry.
In the last couple of years the Gross Margin of PHIL has grown nicely.
Industry RankSector Rank
OM 49.47%
PM (TTM) 58.33%
GM 74.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y40.66%
GM growth 3YN/A
GM growth 5Y18.26%
PHIL.MI Yearly Profit, Operating, Gross MarginsPHIL.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

9

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so PHIL is creating value.
The number of shares outstanding for PHIL remains at a similar level compared to 1 year ago.
The number of shares outstanding for PHIL has been reduced compared to 5 years ago.
The debt/assets ratio for PHIL has been reduced compared to a year ago.
PHIL.MI Yearly Shares OutstandingPHIL.MI Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
PHIL.MI Yearly Total Debt VS Total AssetsPHIL.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

PHIL has an Altman-Z score of 14.82. This indicates that PHIL is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of PHIL (14.82) is better than 93.42% of its industry peers.
The Debt to FCF ratio of PHIL is 0.31, which is an excellent value as it means it would take PHIL, only 0.31 years of fcf income to pay off all of its debts.
PHIL has a better Debt to FCF ratio (0.31) than 92.11% of its industry peers.
A Debt/Equity ratio of 0.08 indicates that PHIL is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.08, PHIL is doing good in the industry, outperforming 64.47% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 0.31
Altman-Z 14.82
ROIC/WACC2.6
WACC8.12%
PHIL.MI Yearly LT Debt VS Equity VS FCFPHIL.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

PHIL has a Current Ratio of 5.73. This indicates that PHIL is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PHIL (5.73) is better than 84.21% of its industry peers.
PHIL has a Quick Ratio of 5.52. This indicates that PHIL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.52, PHIL belongs to the top of the industry, outperforming 85.53% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.73
Quick Ratio 5.52
PHIL.MI Yearly Current Assets VS Current LiabilitesPHIL.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

8

3. Growth

3.1 Past

PHIL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 255.77%, which is quite impressive.
The Earnings Per Share has been growing by 100.72% on average over the past years. This is a very strong growth
Looking at the last year, PHIL shows a very strong growth in Revenue. The Revenue has grown by 3346.54%.
The Revenue has been growing by 42.46% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)255.77%
EPS 3YN/A
EPS 5Y100.72%
EPS Q2Q%3.48%
Revenue 1Y (TTM)3346.54%
Revenue growth 3Y209.5%
Revenue growth 5Y42.46%
Sales Q2Q%606.29%

3.2 Future

The Earnings Per Share is expected to decrease by -3.40% on average over the next years.
The Revenue is expected to grow by 22.55% on average over the next years. This is a very strong growth
EPS Next Y56.07%
EPS Next 2Y-82.09%
EPS Next 3Y-67.13%
EPS Next 5Y-3.4%
Revenue Next Year184.06%
Revenue Next 2Y-47.42%
Revenue Next 3Y-33.73%
Revenue Next 5Y22.55%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
PHIL.MI Yearly Revenue VS EstimatesPHIL.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
PHIL.MI Yearly EPS VS EstimatesPHIL.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4 6 8

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 20.96 indicates a rather expensive valuation of PHIL.
Based on the Price/Earnings ratio, PHIL is valued cheaper than 80.26% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.69. PHIL is valued slightly cheaper when compared to this.
The Price/Forward Earnings ratio is 126.66, which means the current valuation is very expensive for PHIL.
Based on the Price/Forward Earnings ratio, PHIL is valued a bit cheaper than 73.68% of the companies in the same industry.
PHIL's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.18.
Industry RankSector Rank
PE 20.96
Fwd PE 126.66
PHIL.MI Price Earnings VS Forward Price EarningsPHIL.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PHIL is valued cheaper than 81.58% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHIL indicates a rather cheap valuation: PHIL is cheaper than 82.89% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 18.98
EV/EBITDA 12.13
PHIL.MI Per share dataPHIL.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

PHIL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of PHIL may justify a higher PE ratio.
PHIL's earnings are expected to decrease with -67.13% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.37
PEG (5Y)0.21
EPS Next 2Y-82.09%
EPS Next 3Y-67.13%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PHIL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHILOGEN SPA

BIT:PHIL (10/20/2025, 7:00:00 PM)

23.9

+0.4 (+1.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-23 2025-09-23
Earnings (Next)11-11 2025-11-11
Inst Owners8.18%
Inst Owner ChangeN/A
Ins Owners34.46%
Ins Owner ChangeN/A
Market Cap698.84M
Analysts82.5
Price Target30.6 (28.03%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)1316.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)1.03%
Revenue NY rev (3m)191.65%
Valuation
Industry RankSector Rank
PE 20.96
Fwd PE 126.66
P/S 8.88
P/FCF 18.98
P/OCF 17.67
P/B 5.55
P/tB 5.61
EV/EBITDA 12.13
EPS(TTM)1.14
EY4.77%
EPS(NY)0.19
Fwd EY0.79%
FCF(TTM)1.26
FCFY5.27%
OCF(TTM)1.35
OCFY5.66%
SpS2.69
BVpS4.3
TBVpS4.26
PEG (NY)0.37
PEG (5Y)0.21
Profitability
Industry RankSector Rank
ROA 28.81%
ROE 36.49%
ROCE 28.1%
ROIC 21.08%
ROICexc 75.73%
ROICexgc 78.23%
OM 49.47%
PM (TTM) 58.33%
GM 74.04%
FCFM 46.77%
ROA(3y)5.82%
ROA(5y)-1.99%
ROE(3y)6.79%
ROE(5y)-3.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y40.66%
GM growth 3YN/A
GM growth 5Y18.26%
F-Score8
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 0.31
Debt/EBITDA 0.24
Cap/Depr 67.4%
Cap/Sales 3.47%
Interest Coverage 78.84
Cash Conversion 91.98%
Profit Quality 80.19%
Current Ratio 5.73
Quick Ratio 5.52
Altman-Z 14.82
F-Score8
WACC8.12%
ROIC/WACC2.6
Cap/Depr(3y)124.83%
Cap/Depr(5y)196.93%
Cap/Sales(3y)15.46%
Cap/Sales(5y)79.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)255.77%
EPS 3YN/A
EPS 5Y100.72%
EPS Q2Q%3.48%
EPS Next Y56.07%
EPS Next 2Y-82.09%
EPS Next 3Y-67.13%
EPS Next 5Y-3.4%
Revenue 1Y (TTM)3346.54%
Revenue growth 3Y209.5%
Revenue growth 5Y42.46%
Sales Q2Q%606.29%
Revenue Next Year184.06%
Revenue Next 2Y-47.42%
Revenue Next 3Y-33.73%
Revenue Next 5Y22.55%
EBIT growth 1Y218.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.38%
EBIT Next 3Y-70.2%
EBIT Next 5YN/A
FCF growth 1Y1324.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6769.31%
OCF growth 3YN/A
OCF growth 5Y135.99%